Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device

References

• GhanyMGStraderDBThomasDLSeeffLBDiagnosis, management, and treatment of hepatitis C: an updateHepatology20094941335137419330875
   PubMed Web of Science ®Google Scholar
• LokASMcMahonBJChronic hepatitis B: update 2009Hepatology200950366166219714720
   PubMed Web of Science ®Google Scholar
• ZeuzemSWelschCHerrmannEPharmacokinetics of peginterferonsSemin Liver Dis200323Suppl 1232812934165
   PubMed Web of Science ®Google Scholar
• PedderSCPegylation of interferon alfa: structural and pharmacokinetic propertiesSemin Liver Dis200323Suppl 1192212934164
   PubMed Web of Science ®Google Scholar
• PegasysSummary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000395/WC500039196.pdfAccessed September 20, 2011
   Google Scholar
• Schering CorporationPegIntron ^® (peginterferon alfa-2b) prescribing information http://www.spfiles.com/pipeg-intron.pdfAccessed October 7, 2011
   Google Scholar
• Hoffmann-La Roche IncMedication Guide. Pegasys®Solution for subcutaneous injection Available from: http://www.gene.com/gene/products/information/pegasys/pdf/Pegasys_MedGuide.pdfAccessed October 7, 2011
   Google Scholar
• National Institute for Occupational Safety and HealthPreventing needlestick injuries in health care settings Available from: http://www.cdc.gov/niosh/docs/2000-108/Accessed September 22, 2011
   Google Scholar
• CoxDStoneJManaging self-injection difficulties in patients with relapsing-remitting multiple sclerosisJ Neurosci Nurs200638316717116817668
   PubMedGoogle Scholar
• DevonshireVArbizuTBorreBPatient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb studyBMC Neurol20101012820433746
   PubMed Web of Science ®Google Scholar
• KivitzACohenSDowdJEClinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trialClin Ther200628101619162917157117
   PubMed Web of Science ®Google Scholar
• PaulCStalderJThaciDPatient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasisJ Eur Acad Dermatol Venereol2011 [Epub ahead of print]10.1111/j.1468-3083.201104093.x
   Google Scholar
• BerteauCSchwarzenbachFDonazzoloYEvaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteersPatient Prefer Adherence2010437938821049090
   PubMed Web of Science ®Google Scholar
• Borras-BlascoJGracia-PerezARosique-RoblesJDCasteraMDAbadFJAcceptability of switching adalimumab from a prefilled syringe to an autoinjection penExpert Opin Biol Ther201010330130720059372
   PubMed Web of Science ®Google Scholar
• GraffMRMcClanahanMAAssessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringeClin Ther19982034864969663364
   PubMed Web of Science ®Google Scholar
• LeeWCBaluSCobdenDJoshiAVPashosCLMedication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims dataClin Ther200628101712172517157128
   PubMed Web of Science ®Google Scholar
• RubinRRPeyrotMQuality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/ soluble aspart) versus alternative treatment strategiesDiabetes Care200427102495249715451924
   PubMed Web of Science ®Google Scholar
• AlgranatiNSySModiMA branchedmethoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2A and may explain its enhanced efficacy in chronic hepatitis C (CHC) [abstract]Hepatology199930Suppl Pt 2190
   Google Scholar
• MatinMModiMCharacterization of pegylated (40 kDa) interferon alfa-2a (Pegasys) in the elderly [abstract]Hepatology200032Suppl Pt 234810915742
   PubMed Web of Science ®Google Scholar
• ModiMFriedMReindollarRThe pharmacokinetic behavior of pegylated (40 kDa) interferon alfa-2a (Pegasys) in chronic hepatitis C patients after multiple dosing [Abstract]Hepatology200032Suppl Pt 239410915748
   PubMed Web of Science ®Google Scholar
• RocheHoffmann-LaA Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis Cclinicaltrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)392010 [last updated on June 15, 2011]Available from: http://clinicaltrials.gov/ct2/show/NCT01087944NLM identifier: NCT01087944
   Google Scholar
• NieforthKANadeauRPatelIHMouldDUse of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjectsClin Pharmacol Ther19965966366468681488
   PubMed Web of Science ®Google Scholar
• ZeuzemSFeinmanSVRasenackJPeginterferon alfa-2a in patients with chronic hepatitis CN Engl J Med2000343231666167211106715
   PubMed Web of Science ®Google Scholar
• XuZ-XHoffmanJPatelIJoubertPSingle-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon a-2a (IFN a-2a) to healthy subjects [Abstract]Hepatology199828702A
   Web of Science ®Google Scholar
• Genetech USA IPegasys full prescribing information and medication guide Available from: http://www.gene.com/gene/products/information/pegasys/pdf/pi.pdfAccessed October 7, 2011
   Google Scholar
• OgawaLSubstance use experiences and hepatitis c treatment decisionmaking among HIV/HCV co-infected adults: A dissertation2007University of Massachusetts Medical School GSN Dissertations Paper 3
   Google Scholar
• BovaCOgawaLSullivan-BolyaiSHepatitis C treatment experiences and decision-making among patients living with HIV infectionJ Assoc Nurses AIDS Care201021637419853480
   PubMed Web of Science ®Google Scholar
• HaganHPougetERDesJA systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugsJ Infect Dis20112041748321628661
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med2005353548749716079372
   PubMed Web of Science ®Google Scholar
• SimpsonSHEurichDTMajumdarSRA meta-analysis of the association between adherence to drug therapy and mortalityBMJ2006333755715
   PubMed Web of Science ®Google Scholar
• [No authors listed]Poor adherence to long-term treatment of chronic diseases is a worldwide problemRev Panam Salud Publica200314321822114653913
   PubMedGoogle Scholar
• CacoubPOuzanDMelinPPatient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational studyWorld J Gastroenterol200814406195620318985810
   PubMed Web of Science ®Google Scholar
• McHutchisonJGMannsMPatelKAdherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis CGastroenterology200212341061106912360468
   PubMed Web of Science ®Google Scholar
• HughesCAShafranSDChronic hepatitis C virus management: 2000–2005 updateAnn Pharmacother2006401748216368925
   PubMed Web of Science ®Google Scholar
• FontangesTBeorchiaSDouvinCSafety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infectionGastroenterol Clin Biol2007316–756657217646782
   PubMedGoogle Scholar
• FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J Med20023471397598212324553
   PubMed Web of Science ®Google Scholar
• HadziyannisSJSetteHJrMorganTRPeginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseAnn Intern Med2004140534635514996676
   PubMed Web of Science ®Google Scholar
• AlterMJEpidemiology of hepatitis CHepatology199726Suppl 162S65S9305666
   PubMed Web of Science ®Google Scholar
• United States General Accounting OfficeOccupational safety: selected cost and benefit implications of needlestick prevention devices for hospitals Document GAO-01-60RWashington, DC2000
   Google Scholar
• JacobsonIMMcHutchisonJGDusheikoGTelaprevir for previously untreated chronic hepatitis C virus infectionN Engl J Med2011364252405241621696307
   PubMed Web of Science ®Google Scholar
• ZeuzemSAndreonePPolSTelaprevir for retreatment of HCV infectionN Engl J Med2011364252417242821696308
   PubMed Web of Science ®Google Scholar
• PoordadFMcConeJJrBaconBRBoceprevir for untreated chronic HCV genotype 1 infectionN Engl J Med2011364131195120621449783
   PubMed Web of Science ®Google Scholar
• BaconBRGordonSCLawitzEBoceprevir for previously treated chronic HCV genotype 1 infectionN Engl J Med2011364131207121721449784
   PubMed Web of Science ®Google Scholar
• Merck & Co IVictrelis (boceprevir) prescribing information Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdfAccessed October 7, 2011
   Google Scholar
• Vertex Pharmaceuticals LtdIncivek (telaprevir) prescribing information Available from: http://www.natap.org/2011/HCV/INCIVEKUSPI.pdfAccessed October 7, 2011
   Google Scholar